Clinical Trial Detail

NCT ID NCT02785913
Title Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

lung squamous cell carcinoma

Therapies

Taselisib

Age Groups: adult

No variant requirements are available.